Citigroup
MYGN icon

Citigroup’s Myriad Genetics MYGN Stock Holding History

Citigroup’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-47,200
Closed -$933K – 7002
2020
Q4 		$933K Buy
47,200
+1,400
+3% +$22.6K ﹤0.01% 3603
2020
Q3 		$597K Sell
45,800
-35,800
-44% -$453K ﹤0.01% 3707
2020
Q2 		$925K Sell
81,600
-26,900
-25% -$382K ﹤0.01% 3633
2020
Q1 		$1.55M Buy
108,500
+17,200
+19% +$363K ﹤0.01% 2738
2019
Q4 		$2.49M Buy
91,300
+83,800
+1,117% +$2.31M ﹤0.01% 2760
2019
Q3 		$215K Sell
7,500
-3,600
-32% -$105K ﹤0.01% 5093
2019
Q2 		$308K Buy
11,100
+6,900
+164% +$195K ﹤0.01% 4894
2019
Q1 		$140K Buy
4,200
+2,900
+223% +$88.3K ﹤0.01% 5438
2018
Q4 		$38K Sell
1,300
-2,600
-67% -$93.5K ﹤0.01% 6451
2018
Q3 		$179K Buy
3,900
+2,600
+200% +$116K ﹤0.01% 5369
2018
Q2 		$49K Buy
+1,300
New +$43.9K ﹤0.01% 6303
2018
Q1 		– Sell
-1,300
Closed -$45K – 7619
2017
Q4 		$45K Sell
1,300
-49,600
-97% -$1.67M ﹤0.01% 6253
2017
Q3 		$1.84M Buy
50,900
+45,000
+763% +$1.28M ﹤0.01% 2739
2017
Q2 		$152K Sell
5,900
-1,600
-21% -$34K ﹤0.01% 5017
2017
Q1 		$144K Buy
7,500
+4,700
+168% +$83.3K ﹤0.01% 4931
2016
Q4 		$47K Sell
2,800
-300
-10% -$5.43K ﹤0.01% 6174
2016
Q3 		$64K Buy
3,100
+2,600
+520% +$65.9K ﹤0.01% 5503
2016
Q2 		$15K Buy
+500
New +$17.4K ﹤0.01% 6319
2016
Q1 		– Sell
-200
Closed -$9K – 7646
2015
Q4 		$9K Sell
200
-1,300
-87% -$54.9K ﹤0.01% 6861
2015
Q3 		$56K Buy
1,500
+1,400
+1,400% +$49.7K ﹤0.01% 5366
2015
Q2 		$3K Buy
+100
New +$3.4K ﹤0.01% 6998

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup's MYGN Position: Q1 2026 in Review

Citigroup reduced its Myriad Genetics (MYGN) stake by 53% in Q1 2026, selling an estimated $98.6K and leaving 17,007 shares worth $76.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4374.

Citigroup first reported a position in MYGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.58M in Q4 2018. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Citigroup held 17,007 shares of Myriad Genetics worth $76.5K as of Q1 2026.
  • Citigroup sold 18,923 Myriad Genetics shares in Q1 2026, an estimated $98.6K.
  • Myriad Genetics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4374 holding.
  • Citigroup first reported a position in Myriad Genetics in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Myriad Genetics position peaked at $6.58M in Q4 2018.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.